Business
Lantern To Participate in H.C Wainwright & Co.’s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference
Lantern Pharma will present virtually on Thursday, March 7th at 2 pm Eastern. Lantern’s CEO & President, Mr. Panna Sharma will be interviewed in the form of
About this update from Lantern Pharma Inc.
[{"type":"text","content":"\n\nLantern Pharma will present virtually on Thursday, March 7th at 2 pm Eastern.\n\n\n\nLantern’s CEO & President, Mr. Panna Sharma will be interviewed in the form of a fireside chat by HCW’s Healthcare & Life Sciences Analyst and Director of Equity Research\n\n\n\nInstitutional investors, companies, and industry professionals are encouraged to register at this link or contact their representative at HCW.\n\n\n\n DALLAS--(BUSINESS WIRE)--\nLantern Pharma Inc. (NASDAQ: LTRN), a leader in AI-driven cancer drug discovery and development, announced that it will be presenting at a virtual conference being hosted by HCW. The conference will be on Thursday, March 7th, and is a virtual event.\n\n\nLantern Pharma’s CEO, Mr. Panna Sharma, will be discussing and presenting via a fireside chat format at The 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference at approximately 2 pm Eastern / 11 am Pacific. While addressing AI in drug discovery, Mr. Sharma will talk about how RADR®, Lantern’s proprietary AI platform, is transforming the cost, pace, and timeline of oncology drug development.\n\n\nEarlier this week, Lantern Pharma announced that RADR® has surpassed 60 billion data points and will reach 100 billion data points during 2024, making innovation in developing cancer therapies potentially more precise, durable, and personalized.\n\n\nInvestors, companies and industry professionals are encouraged to register for the event in advance at this link or contact their HCW representative for more information.\n\n\nAbout RADR®\n\n\nRADR® is Lantern Pharma’s proprietary integrated AI platform for large-scale biomarker and drug-tumor interaction data analytics that leverages machine learning. It is used to provide mechanistic insights about drug-tumor interactions, predict the potential response of cancer types and subtypes to existing drugs and drug candidates, and uncover patient groups that may respond to potential therapies being developed by Lantern Pharma and its collaborators.\n\n\nRADR® uses an ensemble-based approach to apply its library of algorithms to statistical, correlative, and inferential problems in drug-tumor interactions. This allows the platform to rapidly analyze large amounts of complex data and predict how both patients and tumors will respond to therapeutic combinations. RADR® also evo...